The latest global regulatory news, changes and updates affecting biopharma.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Algernon, Biontech, Clarity, Janssen, Mallinckrodt, Novartis, Pfizer, Vitro.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ablexis, Alkermes, Alpha Cognition, Anticancer, Applied Biomath, Asklepios, Avacta, Bayer Bonus Biogroup, Brainvectis, Caladrius, Cellphire, Cocrystal Pharma, Cormedix, Cyclica, Emergex Vaccines, Envisagenics, Etherna, Evotec, Frame, Gilead, Hoth, Immunic, Johnson & Johnson, Kalos, Kite, Linical, Northern Biologics, Nuritas, Oncology Venture, Onko-innate, Pharnext, Q Biomed, Sanofi, Som, Targovax, Valo, Wize, Wuxi, Zylö Therapeutics.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actelion, Astrazeneca, Bluebird, Boehringer, Exelixis, GSK, Harbour, Imbrium, Immutep, Incyte, Intra-Cellular, Kiniksa, Levo, Lilly, Prothena, Neoimmunetech, Regeneron, Regenxbio, Roche, Saniona, Sojournix, Tersera, UCB, United Therapeutics.

Biopharmas raising money in public or private financings, including: Actinium, Arcturus, Calithera, Cyclacel, Forx, Myosana, Migvax, Realta Life Sciences, VBI.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied Therapeutics, Arcutis, Atyr, Cara, Catalyst, CSL Behring, Erytech, Hookipa, Idera, Novartis, Oncoimmune, Synexis.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainlab, Inspire Medical Systems, Labcorp, Roche.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advarra, Amc Health, Archerdx, Centogene, Cerus, Curetis, Evicore Healthcare, Karolinska Institutet, Kurin, Opgen, Oxford Immunotec, Premier, Science 37, Simplify Medical, Vizient.

LONDON – The search for modulators of the immune cascade that is the cause of the most severe respiratory symptoms of COVID-19 is intensifying, with Cyclacel Pharmaceuticals Inc. and Pharming Group NV adding their drugs to the list of repurposing projects.